Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06446453 · ClinicalTrials.gov registry record · NA

Echography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure

A NA study of Respiratory Distress Syndrome, Newborn and Intensive Care Units, Neonatal, sponsored by Connecticut Children's Medical Center.

Recruiting
Registry status
NA
Development phase
52
Enrollment target
1
Study location

NCT06446453: Recruiting NA study of Respiratory Distress Syndrome, Newborn and Intensive Care Units, Neonatal, sponsored by Connecticut Children's Medical Center.

NCT06446453 is a NA study of Respiratory Distress Syndrome, Newborn and Intensive Care Units, Neonatal that is actively recruiting participants, run by Connecticut Children's Medical Center. The registered enrollment target is 52 participants, below the 201-participant average among 8 other Respiratory Distress Syndrome, Newborn trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06446453, a NA study of Respiratory Distress Syndrome, Newborn and Intensive Care Units, Neonatal, is actively recruiting participants, sponsored by Connecticut Children's Medical Center.

RECRUITING
Registry status
NA
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

Point-of-care ultrasound (POCUS) is the use of ultrasound by the bedside provider in real time to answer a specific question and guide medical management. POCUS can be used to diagnose the severity of neonatal respiratory distress syndrome (RDS) through a lung ultrasound score. Lung ultrasound scores have also been shown to predict if an infant is treated with an initial dose of surfactant. Therefore, using lung ultrasound scores to guide surfactant therapy for RDS will likely lead to earlier surfactant therapy and may improve short-term respiratory outcomes. This study will test this theory by comparing lung ultrasound score-guided surfactant therapy for premature infants with RDS with our current surfactant administration guidelines.

Primary Outcome

(CPAP Level x FiO2)/(SpO2)

Interventions

  • DIAGNOSTIC_TEST Echography-guided Surfactant THERapy (ESTHER)

Study Locations (1)

Connecticut

  • Connecticut Children's - Hartford

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2024-06-25
Est. Completion 2026-06
Phase NA

What NCT06446453 shows while recruiting

NCT06446453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 201-participant average among 8 other Respiratory Distress Syndrome, Newborn trials with a reported enrollment target (74% lower).

The record links to 3 conditions, with Respiratory Distress Syndrome, Newborn appearing as the primary indexed condition, and to 1 intervention - of which Echography-guided Surfactant THERapy (ESTHER) is the first listed.

NCT06446453 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT06446453 about?

NCT06446453 is a clinical study titled "Echography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure". Point-of-care ultrasound (POCUS) is the use of ultrasound by the bedside provider in real time to answer a specific question and guide medical management. POCUS can be used to diagnose the severity of neonatal respiratory distress syndrome (RDS) through a lung ultrasound score. Lung ultrasound score...

What is the current status of trial NCT06446453?

This trial is currently recruiting. It is a NA study. The enrollment target is 52 participants. The study started on 2024-06-25. Estimated completion is 2026-06.

What conditions does trial NCT06446453 study?

This clinical trial studies the following conditions: Respiratory Distress Syndrome, Newborn, Intensive Care Units, Neonatal, Pulmonary Surfactants.

What interventions are being tested in trial NCT06446453?

The interventions under investigation include: Echography-guided Surfactant THERapy (ESTHER) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06446453?

This trial is sponsored by Connecticut Children's Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06446453 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Respiratory Distress Syndrome, Newborn

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06446453's enrollment target sits among peer trials

52 7th of 8 higher than 2 of 8 other Respiratory Distress Syndrome, Newborn trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Respiratory Distress Syndrome, Newborn trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06446453, the US trial registry maintained by the National Library of Medicine. NCT06446453 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.